Work

371P Targeting GREM1 reprograms the tumor microenvironment of lung adenocarcinoma liver metastases and enhances anti-tumor responses to anti-PD-1 immunotherapy

Year: 2025

Type: article

Abstract: Patients with driver gene-negative lung adenocarcinoma (LUAD) and liver metastasis usually have a poorer prognosis. Although immune checkpoint inhibitors (ICIs) demonstrate therapeutic effects, liver metastasis significantly diminishes the efficacy of ICIs. Recent studies indicate that Grem1, a secreted protein, plays a role in the development of various malignant tumors. However, its specific mechanism in immune regulation of LUAD liver metastases remains unclear.

Source: Immuno-Oncology Technology

DOI: 10.1016/j.iotech.2025.101368

Authors: Q. Zheng, Q. Zhang, Z. Liang

Institution: Nanjing Second Hospital

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,340